Nov. 12, 2009 (PR Newswire) — CORALVILLE, Iowa, Nov. 12 /PRNewswire-FirstCall/ — Vivakor, Inc. (OTC Bulletin Board: VIVK) is the keynote presenting company at the founders’ celebration of consumer product specialist, Regeneca International, Inc. (www.regeneca.com). The celebration will be attended by over 200 founders and guests of Regeneca International from across the United States. It will be hosted at the prestigious Balboa Bay Club in Newport Beach, California. Vivakor’s Chairman, Matt Nicosia and CFO, Ed Corrente will both be attending the event.

Event attendee, Dr. Brian Scott , a Regeneca advisory board member and nationally recognized wellness expert, was particularly pleased to learn of Vivakor’s role in the event. “As a healthcare provider and speaker on issues regarding wellness and longevity, it is refreshing to hear the perspective of a company, doing business internationally, which can provide a particular focus on products which extend the length and

...

At its investor conference call, Monsanto Company (MON) indicated that it will accelerate launches for its Genuity SmartStax corn and Genuity Roundup Ready 2 Yield soybean products. The company emphasized its growth strategy from 2010 through 2012, which includes three operational imperatives: the conversion to Genuity SmartStax in U.S. corn, the upgradation to the Genuity Roundup Ready 2 Yield platform in U.S. soybeans, and increased penetration in Latin America. Monsanto now anticipates its new Genuity SmartStax corn seed will launch on more than 4 million acres in 2010, compared to its previous expectation of 3 million to 4 million acres. As a part of the accelerated adoption of Genuity SmartStax, the company unveiled a new portfolio of product upgrades for key U.S. corn segments. For the Genuity Roundup Ready 2 Yield platform in U.S. soybeans, Monsanto increased its launch-year expectation for 2010 to 8 - 10 ...

SurModics’ (SRDX) fourth-quarter earnings per share came in at 18 cents, below the Zacks Consensus Estimate of 20 cents. The company reported revenues of $19.2 million, down 17% compared to the year ago period. In addition to quarterly results, SurModics came out with fiscal year 2009 results. The company recorded revenues of $121.5 million in 2009, up 25%, compared to $97 million in the previous year and earnings per share of $1.07 for 2009.

On a business unit basis, apart from Diagnostic, revenues from the other three segments – Cardiovascular, Ophthalmology and Other Markets, recorded a decline in revenues for the fourth quarter. While Diagnostic revenues increased 2% year over year to $4.6 million, revenues for the other three segments declined 12% to $9.8 million, 29% to $1.9 million and 41% to $2.9 million, respectively.

Cardiovascular segment results were impacted by the continuing decline in Cypher sales. SurModics derives a substantial

...

On a late Thursday evening, Celera Corporation (NASDAQ:CRA) and Medical Therapies Limited have announced that they have entered an exclusive license agreement for the use of Medical Therapies’ midkine patent portfolio for the development of novel lung cancer diagnostics. According to the license agreement, Celera will be able to use the Medical Therapies’ midkine patents for the commercialization and development of diagnostic products to address a range of lung cancer related applications which includes risk assessment, differentiation, prognosis, early detection system, disease progression, response to treatment and monitoring of reoccurrence. Celera Corporation and Medical Therapies Limited both are happy about the intellectual property agreement.

Celera Corporation is one of the upcoming healthcare companies that handles personalized disease management products and services and looks after three main segments which

...

For Immediate Release

Chicago, IL – October 28, 2009 – Zacks Equity Research highlights Cooper Tire & Rubber Co. (CTB) as the Bull of the Day and Citi Trends (CTRN) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Life Technologies Corporation (LIFE), MDS Analytical Technologies (MDS) and Danaher Corporation (DHR).

Full analysis of all these stocks is available at http://at.zacks.com/?id=2676

Here is a synopsis of all five stocks:

Bull of the Day:

Cooper Tire & Rubber Co. (CTB) is well positioned to enjoy improved operating costs, greater geographic flexibility and the ability to penetrate international markets through its investments and facilities in low-cost countries.

The company continues to realize the benefits of reducing costs in its manufacturing operations. It has also been able to absorb the costs associated with the need to curtail production to align

...

In 1996, Frederic Scheer had a vision when he began to market the concept of compostable plastics. This vision led Cereplast from a pioneer to a leader in the bioplastics industry. Yesterday, the vision of Mr. Scheer and the team at Cereplast provided a breakthrough announcement that will change the face of their industry forever with the transformation of algae into bioplastics.

Cereplast has developed breakthrough technology to transform algae into bioplastics with the intention to launch a new family of algae-based resins that will complement the company’s existing line of Compostables and Hybrid resins.

If successful, Cereplast algae-based resins could replace over 50% of the petroleum content used in plastic resins, possibly having a profound effect on the oil industry. Such companies as Exxon and BP have started to invest money in the algae production business because of the potential in their industry.

Mr. Scheer, who is not only

...

Today before the market opened, Monsanto Co. (MON), the largest chemicals and biotech seed maker reported results for the fourth quarter of fiscal year 2009, ended August 31, 2009. Excluding one-time items (on an ongoing basis), the company reported earnings of 2 cents per share, compared to a loss of 3 cents per share in the year-ago quarter. This was above the Zacks Consensus Estimate of 1 cent per share. However, the company posted a wider loss in the quarter, which increased to 43 cents per share on an as-reported basis, from 31 cents in the year-ago quarter, due to restructuring charges and the divestiture of the company's sunflower operations. Restructuring lowered earnings by 53 cents. During the quarter, the company also increased the restructuring reserve to the $550 - $600 million range to support its cost-cutting effort. SG&A as a percentage of revenue was ...

It’s a difficult question to ponder as the state of the world economy is so fragile. Right now, GDP growth stems exclusively from the government’s stimulus package. But once Obama and his cronies are finished fixing the economy, what will the fuel the next leg of the recovery?

In the near term, we think the prospects for job growth look incredibly bleak. Banks aren’t lending. Companies aren’t hiring or investing heavily in R&D, and corporate profits are up only because of cost cutting measures, like layoffs, rather than bottom line revenue growth.

In the long term, however, certain industries look primed to blossom like plastics did in the 70s and semiconductors, personal PCs, and telecom did in the 80s and 90s. Barry Ritholtz at The Big Picture points out ten niche industries he thinks will fill in the gaps and push the world economy forward. Here are his top ten (listed in order

...

Monsanto Corp. (NYSE: MON), the world’s largest seed maker, says it’s on track to more than double its 2007 profit by the year 2012 and is expecting a “technology explosion” to provide even stronger products going forward. But while Monsanto continues to build on its reputation as a cutting edge agricultural business, it is also under siege by competitors and advocacy groups who claim the company is a monopoly.

The St. Louis-based Monsanto said in June that its fiscal third-quarter earnings fell to $694 million, or $1.25 a share, from $811 million, or $1.45 a share, in the same period a year ago. Sales slipped to $3.16 billion from $3.54 billion last year. The company also said its annual earnings would likely be at the low end of its $4.40 to $4.50 a share forecast range.

That’s not very impressive for a company that last year posted record net sales

...

Currently, medicine is, to a large degree, a “one size fits all” proposition. Doctors watch for adverse effects and check personal and family histories. Medical technologies, however, are designed for the general population, not individuals. That’s going to change.

Moreover, there will be huge profit opportunities, in many enabling technologies, for those who invest accordingly. And today I’m going to tell you about a company that will hand you your best chance to make a transformational fortune.

We know that many current treatments work on some people, yet not others. Some drugs are safe for many people, but have dangerous side effects for others. This is because all of us have individual differences in our genetic code based on heredity and environment. Even slight differences can lead to very different reactions to medications.

This has created serious regulatory problems. Drugs are denied regulatory approval not because they do not work, but because some

...